To evaluate feasibility, acceptability, continuation, and trough serum levels following self-administration of subcutaneous (sc) depot medroxyprogesterone acetate (DMPA).
Women presenting to a family planning clinic to initiate, restart or continue DMPA were offered study entry. Participants were randomized in a 2:1 ratio to self- or clinician administered sc DMPA 104 mg. Those randomized to self-administration were taught to self-inject and were supervised in performing the initial injection; they received printed instructions and a supply of contraceptive injections for home use. Participants randomized to clinician administration received usual care. Continued DMPA use was assessed by self-report and trough medroxyprogesterone acetate levels at 6 and 12 months.
Two hundred fifty women were invited to participate, and 137 (55%) enrolled. Of these, 91 were allocated to self-administration, and 90/91 were able to correctly self-administer sc DMPA. Eighty-seven percent completed follow-up. DMPA use at 1 year was 71% for the self-administration group and 63% for the clinic group (p=0.47). Uninterrupted DMPA use was 47% and 48% for the self and clinic administration groups at 1 year (p=0.70), respectively. Serum analyses confirmed similar mean DMPA levels in both groups and therapeutic trough levels in all participants.
Sixty-three percent of women approached were interested in trying self-administration of DMPA, even in the context of a randomized trial, and nearly all eligible for enrollment were successful at doing so. Self-administration and clinic administration resulted in similar continuation rates and similar DMPA serum levels. Self-administration of sc DMPA is feasible and may be an attractive alternative for many women.
Self-administration of sc DMPA is a feasible and attractive option for many women. Benefits include increased control over contraceptive measures and less time spent on contracepting behaviors. Globally, self-administration has the potential to revolutionize contraceptive uptake by increasing the number of women with access to DMPA.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Improving contraceptive use in the United States.in: Brief. Guttmacher Institute, New York2008
- Contraceptive discontinuation attributed to method dissatisfaction in the United States.Contraception. 2007; 76: 267-272
- Depot medroxyprogesterone acetate: Patterns of use and reasons for discontinuation.Contraception. 1997; 56: 209-214
- Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.J Adolesc Health. 1998; 23: 81-88
- Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem.Contraception. 1997; 56: 301-304
- Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.Contraception. 2012; 85: 453-457
- Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.Contraception. 2012; 85: 458-464
- Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.Contraception. 2013; 88: 401-407
- Medical eligibility criteria for contraceptive use. WHO Press, Geneva2004 (Available from:)
- Depo now: preventing unintended pregnancies among adolescents and young adults.J Adolesc Health. 2007; 40: 22-28
- depo-subQ provera 104(r) medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL: physician information. Pharmacia and Upjohn Company, New York2009 (Available from:)
- Self pregnancy testing in an urban family planning clinic: promising results for a new approach to contraceptive follow-up.Contraception. 2008; 77: 40-43
- Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of Depo-MPA.J Clin Endocrinol Metab. 1977; 44: 32-39
- Pharmacokinetics of depot medroxyprogesterone acetate contraception.J Reprod Med. 1996; 41: 381-390
- Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.Contraception. 2010; 82: 160-167
- The acceptability of self-administration of subcutaneous Depo-Provera.Contraception. 2005; 72: 14-18
- Self-injection of monthly combined hormonal contraceptive.Contraception. 2006; 73: 53-55
- Blood levels of medroxyprogesterone acetate after multiple injections of DepoProvera or CycloProvera.Contraception. 1979; 20: 1-4
- Home-based administration of depo-subQ provera 104(tm) in the Uniject(tm) Injection System: A literature Review.Seattle, PATH2011
Published online: February 10, 2014
Accepted: January 31, 2014
Received in revised form: January 30, 2014
Received: December 10, 2013
☆Financial disclosures: Carolyn Westhoff is a consultant to Merck, Agile, and Bayer. The other authors did not report any potential conflicts of interest.
☆☆ClinicalTrials.gov Identifier: NCT01019369.
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.